Assessing 4D Molecular Therapeutics: Insights From 7 Financial Analysts
Assessing 4D Molecular Therapeutics: Insights From 7 Financial Analysts
评估4d分子治疗：7位财务分析师的见解
During the last three months, 7 analysts shared their evaluations of 4D Molecular Therapeutics (NASDAQ:FDMT), revealing diverse outlooks from bullish to bearish.
上个季度，7位分析师对4d分子治疗（纳斯达克：FDMT）进行了评估，展示了从看好到看淡的不同展望。
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
下表总结了他们最近的评级，展示了过去30天内不断变化的情绪，并将其与前几个月进行了比较。
Analysts have recently evaluated 4D Molecular Therapeutics and provided 12-month price targets. The average target is $45.43, accompanied by a high estimate of $63.00 and a low estimate of $36.00. This current average reflects an increase of 10.35% from the previous average price target of $41.17.
分析师们最近对4d分子治疗进行了评估，并提供了为期12个月的目标价。平均目标是45.43美元，高估值为63.00美元，低估值为36.00美元。当前的平均目标反映了比前一个平均目标价格41.17美元增长了10.35%。
Understanding Analyst Ratings: A Comprehensive Breakdown
分析师评级：全面解析
A comprehensive examination of how financial experts perceive 4D Molecular Therapeutics is...
最近分析师行动对4d分...
登录免费看全文
登录/注册